Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma.

Gastric Cancer 2018 May 16;21(3):473-480. Epub 2017 Aug 16.

Australasian Gastro-Intestinal Trials Group, Camperdown, Australia.

Background: The INTEGRATE phase II multinational randomized controlled trial demonstrated the activity of regorafenib on progression-free survival (PFS) in patients with refractory advanced gastric adenocarcinoma. We sought to evaluate whether these PFS gains had the potential to be offset by quality of life (QoL) impacts from treatment side effects and to thereby determine the appropriateness of continuing development to phase III.

Methods: QoL was assessed in INTEGRATE at baseline and at each 4 weeks thereafter, until discontinuation of study treatment, using the QLQ-C30, STO22, and EQ-5D questionnaires. The patient disease and treatment assessment (PTDATA) form was also provided to English-speaking participants. Randomized groups were compared on the QLQ-C30, STO22, and EQ-5D scales using a repeated-measures model; the frequency of troublesome symptoms and side effects measured by the PTDATA form; and deterioration-free survival (DFS). The prognostic value of baseline QoL information was also evaluated.

Results: Of the 147 eligible randomized patients, 142 consented to participate in the QoL substudy, 136 completed a baseline QoL assessment, and 95 completed at least one post-baseline QoL assessment. The DFS rate was significantly improved with regorafenib, and there was no compelling statistical evidence that regorafenib had a broad negative effect across the spectrum of QoL indices evaluated. Fatigue, anxiety, appetite loss, and pain were among the issues most commonly reported for both randomized groups. Baseline levels of pain, appetite, constipation, and physical functioning were prognostic factors for survival.

Conclusions: Regorafenib improved DFS without an excessively negative effect on QoL. Progressing development to the phase III setting is warranted.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10120-017-0754-1DOI Listing
May 2018
66 Reads

Publication Analysis

Top Keywords

baseline qol
8
gastric adenocarcinoma
8
qol
8
randomized groups
8
side effects
8
refractory advanced
8
advanced gastric
8
development phase
8
quality life
8
qol assessment
8
qlq-c30 sto22
8
sto22 eq-5d
8
regorafenib
5
147 eligible
4
evaluatedresults 147
4
prognostic baseline
4
survival dfs
4
dfs prognostic
4
eligible randomized
4
qol evaluatedresults
4

References

(Supplied by CrossRef)

HS Kim et al.
Ann Oncol 2013

GD Demetri et al.
Lancet 2013

A Grothey et al.
Lancet 2013

N Pavlakis et al.
J Clin Oncol 2016

M Wit De et al.
Support Care Cancer 2014

B Glimelius et al.
Ann Oncol 1997

SH Park et al.
Cancer Chemother Pharmacol 2006

PM Fayers et al.
2001

EuroQol Group et al.
Health Policy 1990

MR Stockler et al.
Lancet Oncol 2007

DB Rubin et al.
2004

Similar Publications